"This is usually given to people when they're on oral medication, and then they need something more than that to control their diabetes," Dr. Bononi explains. It joins a class of medication that has only been around a few years. Three other similar options - two are injected once or tw...
GLP-1 agonists. Byetta became a monstrously successful medication for people with diabetes, including this writer. Full disclosure: I own some shares of stock in Amylin Inc., the company that developed Byetta.
3 Clinical trials have demonstrated that icodec has a long half-life of approximately 1 week, with phase 2 trials in people with type 2 diabetes demonstrating similar glycemic efficacy and safety profiles for icodec and once-daily insulin glargine U100.3-6 ONWARDS is a phase 3a clinical trial ...
(HealthDay)—Type 2 diabetes can be tough to control without medication. But for some people, the thought of daily shots makes them delay or avoid starting insulin therapy. Ad Now, new research offers some hope for thoseinsulinavoiders—a once-a-week insulin injection may someday replace dail...
Once-a-week hemodialysis is increasingly used because it maintains residual renal function without a marked change in life habits. Hemodialysis was introduced once a week in an elderly patient who could not walk because of left hemiplegia, and who had previously refused hemodialysis. The patient wa...
Once‐weekly Trulicity is a type 2 diabetes medication for adults that helps your body release its own insulin and can help improve your A1C and blood sugar numbers. For adults living with T2DM, Trulicity lowers the risk of CV events like heart attack, s
Comparison of medication persistence and adherence in type 2 diabetes using a once-weekly regimen of DPP-4 inhibitor compared with once-daily and twice-daily regimens: a retrospective cohort study of Japanese health insurance claims datadoi:10.1007/s13340-024-00714-9Persistence...
Market authorization granted for Bydureon™ – the first once-weekly medication for Type 2 diabetesTyler GreerFuture Medicinal Chemistry
Eligible patients were aged 18 years or older and had type 2 diabetes with HbA1c 7·0-10·5% (53·0-91·0 mmol/mol) on metformin monotherapy. Patients were randomly assigned (1:1:1:1) by use of an interactive web-response system to once a week treatment with either semaglutide 0·5...
Aim: PIONEER REAL Canada examined real‐world clinical outcomes associated with the use of once‐daily oral semaglutide in adults with type 2 diabetes. Materials and Methods: This was a 34‐ to 44‐week, multicentre, prospective, open‐label, non‐interventional study in adults who were treatment...